InsidersTradesSigma
申报总数
公司
▲ 买入（3 笔）
▼ 卖出（0 笔）
内部人交易记录
首席执行官已披露买入
3
已披露卖出
0
T+90 胜率
100%
T+90 平均收益
+20.4%
基于 2 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Explore the full record of transactions filed by David Matthew T, 首席执行官. Officer active across 1 company, notably CorMedix Inc.. Cumulatively, 6 disclosures have been published. Split: 3 buys · 0 sell. Total volume traded: €12k. Activity tracked since 17 November 2021. The latest transaction was filed on 10 January 2025 (Retenue fiscale). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to David Matthew T
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报6 总计
6,515 股@ US$11.1974.0% 占其流量Common StockSEC:0001213900-25-003535:0
62,500 股0Common StockSEC:0001213900-25-001356:0
50,000 股0Common StockSEC:0000929638-24-000133:0
1,000 股@ US$4.500.0007% mcap16.0% 占其流量Common StockSEC:0001213900-21-064006:0
标准退出：2022年3月6日 (T+90)
1,000 股@ US$4.505.0% 占其流量Common StockSEC:0001213900-21-064007:0
标准退出：2022年3月6日 (T+90)
1,000 股@ US$5.075.7% 占其流量Common StockSEC:0001213900-21-060724:0
标准退出：2022年2月15日 (T+90)
6 条申报中的 6 条
About David Matthew T
Matthew T. David serves as Interim CEO and Chief Financial Officer at CorMedix Inc. He oversees the company's financial and strategic operations, ensuring compliance with regulatory standards. Matthew plays a key role in resource management and supporting growth initiatives.
